เอกสารอ้างอิง :
[1]. Lewis JB, Neilson EG. Glomerular Diseases. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine, 21e. McGraw Hill; 2022. Accessed November 28, 2023. https://accessmedicine.mhmedical.com/content.aspx?bookid=3095§ionid=263549889
[2]. Kazi AM, Hashmi MF. Glomerulonephritis. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560644/
[3]. สมาคมโรคไตแห่งประเทศไทย. 2561. ข้อแนะนำเวชปฏิบัติทั่วไป โรคไตโกลเมอรูลัสในผู้ใหญ่. บริษัท เท็กซ์ แอนด์ เจอร์นัล พับลิเคชั่น จำกัด. https://www.nephrothai.org/wp-content/uploads/2021/10/ข้อแนะนำเวชปฏิบัติทั่วไปโรคไตโกลเมอรูลัสในผู้ใหญ่-2561.pdf
[4]. Kenneth G. Major adverse effects of systemic glucocorticoids. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed on November 13, 2023.)
[5]. Lee YH, Song GG. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis. Pharmacology. 2022;107(9-10):439-445. doi:10.1159/000525066
[6]. Matsumoto H, Nakao T, Okada T, et al. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Intern Med. 2004;43(8):668-673. doi:10.2169/internalmedicine.43.668
[7]. Medjeral-Thomas NR, Lawrence C, Condon M, et al. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial [published correction appears in Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1027]. Clin J Am Soc Nephrol. 2020;15(2):209-218. doi:10.2215/CJN.06180519